Healthcare marketing is never static, and 2025 has been no exception. Over the past year, major advertising platforms introduced new rules that directly impact how health brands can run campaigns, track conversions, and build audiences. Some updates narrowed the options available to patient-facing advertisers, while others opened new doors for B2B health companies targeting professionals.
For health marketers, keeping up with these shifts is critical. Compliance missteps can lead to campaign shutdowns—or worse, regulatory exposure—while missing new opportunities can mean falling behind competitors. Here’s a roundup of the most significant policy changes from 2025.
Meta: From Warnings to Enforcement
Meta has long maintained policies discouraging the use of health-related data in ways that could create protected health information (PHI). But in 2025, the company went from relying on advertisers to self-police to actively enforcing new restrictions.
January 2025: Bottom-funnel conversions restricted
In early 2025, Meta began categorizing advertisers into sensitive industries, including health and wellness, and limiting the events they could use to optimize campaigns. Conversions such as “appointment signup” or “prescription ordered” were flagged as too sensitive to pair with Meta’s user data. The rationale: such combinations could constitute PHI, creating legal and policy risks.
Health advertisers had to adjust by moving away from bottom-funnel signals, instead leaning on compliant setups like anonymized events or higher-funnel engagement signals. For many, this meant rethinking how performance campaigns were structured from the ground up.
July 2025: Automated flagging of audiences and events
By midyear, Meta expanded its enforcement. The platform began proactively scanning and disabling custom audiences, lookalikes, and custom conversions that referenced sensitive health or financial traits—even if those had been previously approved.
Importantly, campaigns using flagged assets weren’t paused outright, but performance degraded quickly if those audiences or conversions were disabled. Advertisers had to rebuild with compliant naming conventions and structures.
Meta’s July update signaled a clear shift: health advertisers can no longer assume borderline tactics will go unnoticed. Instead, Meta is applying automated enforcement to reduce its own liability and push advertisers toward safer practices.
(For more detail, see ADM’s coverage of Meta’s February policy change and July enforcement update.)
LinkedIn: Insight Tag Disabled for Health Domains
At the end of 2024, LinkedIn announced a change that took full effect in 2025: disabling its Insight Tag on domains associated with sensitive consumer data, including healthcare.
What changed
- The Insight Tag can no longer be used on consumer-facing healthcare pages, such as patient portals or medication-specific landing pages.
- It may still be used on generic homepages or B2B-focused pages targeting healthcare professionals, but not on sites where individual health data could be inferred.
Impact on campaigns
- Conversion tracking stops once the tag is disabled.
- Website retargeting audiences shrink as cookie pools disappear.
Workarounds
LinkedIn has suggested several alternatives:
- Conversions API: server-to-server data sharing with more control.
- Engagement-based retargeting: audiences built from actions like video views or ad clicks.
- Matched audiences: first-party data from CRM or contact lists.
B2B health brands can still reach professional audiences on LinkedIn, but consumer-facing campaigns must find new ways to track success without the Insight Tag.
Google: Opening Doors for Professional Audiences
While Meta and LinkedIn tightened rules, Google’s 2025 update gave health advertisers some long-awaited flexibility—at least for B2B targeting.
HCP targeting restored
In July, Google clarified that its ban on personalized health-interest targeting does not apply to licensed healthcare professionals in their professional capacity. That means health brands marketing to physicians, nurses, or other licensed providers can now use Remarketing and Customer Match lists.
This is a significant step forward for B2B campaigns, putting physician-focused brands on more equal footing with other verticals.
Certifications for restricted drug terms
The exception isn’t wide open, though. Advertisers promoting prescription drug products to HCPs must apply for a new certification, confirming compliance with state, federal, and self-regulatory standards. Agencies managing these campaigns need formal authorization from the healthcare company via a letter submitted to Google.
This additional layer of oversight ensures that only vetted advertisers can use Google’s tools to reach HCP audiences for sensitive drug products.
Other Google Policy Tweaks
Google also made a few incremental changes worth noting:
- “Restricted Medical Content” label retired (August 2025): The terminology was removed, but enforcement remains in place. Advertisers shouldn’t assume this signals a loosening of restrictions.
- Drug list changes: For example, melatonin was removed from the restricted list—illustrating how even small adjustments can affect campaign eligibility.
- Tag/GTM updates: Google Tag Manager changes introduced new concerns for healthcare advertisers about inadvertent PHI collection, making tag audits more important than ever.
The Common Thread: Privacy First
Across all three platforms, the theme is the same: patient privacy is driving policy.
- Meta is preventing advertisers from passing sensitive conversion data.
- LinkedIn is blocking its tag from collecting health-related signals on consumer domains.
- Google is cautiously reintroducing personalization for professional audiences, but only with added certification and safeguards.
For health advertisers, 2025 underscored the need to:
- Audit campaign structures and event naming conventions.
- Invest in privacy-safe tools like Conversions APIs and compliant CDPs.
- Differentiate between patient-facing and professional-facing campaigns, which now follow very different rules.
ADM’s Take
If 2024 was a year where compliance became impossible to ignore, 2025 was the year platforms themselves took the lead in enforcing it. For brands, this shift doesn’t have to be a setback—it’s an opportunity to rebuild campaigns in a way that’s both effective and future-proof.
At ADM, we’ve spent the year helping health brands adapt to these changes. From Meta’s event restrictions to Google’s HCP certification process, our focus is on keeping campaigns compliant while still hitting growth goals.
If your team is feeling the weight of these policy updates, reach out—we’ll help you navigate the moving target of health advertising.
